Logo

American Heart Association

  116
  0


Final ID: MDP858

Relationship Between CVH and Survival in the Acoramidis Treated Participants Within ATTRibute-CM

Abstract Body (Do not enter title and authors here): Background: Acoramidis is a novel, potent, investigational, transthyretin (TTR) stabilizer under development for the treatment of TTR amyloidosis that results in near-complete (≥90%) TTR stabilization. In a phase 3 study, ATTRibute-CM, acoramidis demonstrated improved clinical outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM), including a 50% reduction in the risk of CVH compared to placebo over 30 months. The study also demonstrated that cardiovascular hospitalization (CVH) during the study predicted a higher subsequent mortality in participants with ATTR-CM.

Hypothesis: CVH portends a higher risk of mortality in participants with ATTR-CM. Since acoramidis reduces CVH, it can improve the prognosis of participants with ATTR-CM.

Aim: To evaluate the relationship between CVH and survival in the acoramidis group within ATTRibute-CM.

Methods: In this post-hoc analysis, the relationship between those with or without CVH and survival was analyzed within the acoramidis treatment group using the Kaplan-Meier (KM) estimator method.

Results: Demographics and baseline disease characteristics were mostly comparable between acoramidis-treated participants with and without CVH, although participants with CVH had a higher baseline NT-proBNP and lower eGFR. At Month 30, in acoramidis-treated participants, those without any CVH (n=300) had a higher survival [86.8% (95% CI = 82.2, 90.3)] versus 62.4% (95% CI = 52.6, 70.7) in those who had any CVH (n=109); p<0.0001 from log-rank test (Figure).

Conclusion: In the ATTRibute-CM study, pts without any CVH receiving acoramidis have a higher survival rate. CVHs remain a powerful predictor of mortality. This reinforces the importance of an effective therapy that reduces CVH and in turn may improve survival in patients with ATTR-CM.
  • Alexander, Kevin  ( Stanford University , Palo Alto , California , United States )
  • Whang, John  ( BridgeBio Pharma , New York , New York , United States )
  • Fox, Jonathan  ( BridgeBio Pharma , New York , New York , United States )
  • Du, Jing  ( BridgeBio Pharma , New York , New York , United States )
  • Cheng, Richard  ( University of Washington , Seattle , Washington , United States )
  • Davis, Margot  ( UNIVERSITY OF BRITISH COLUMBIA , Vancouver , British Columbia , Canada )
  • Ambardekar, Amrut  ( University of Colorado , Aurora , Colorado , United States )
  • Nativi-nicolau, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Shah, Keyur  ( VIRGINIA COMMONWEALTH UNIVERSITY , Richmond , Virginia , United States )
  • Hanna, Mazen  ( CLEVELAND CLINIC , Cleveland , Ohio , United States )
  • Gibbs, Simon  ( BridgeBio Pharma , New York , New York , United States )
  • Tamby, Jean-francois  ( BridgeBio Pharma , New York , New York , United States )
  • Siddhanti, Suresh  ( BridgeBio Pharma , New York , New York , United States )
  • Author Disclosures:
    Kevin Alexander: DO have relevant financial relationships ; Consultant:Arbor Biotechnologies:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Prothena:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Intellia:Past (completed) ; Consultant:Alnylam:Active (exists now) | John Whang: DO have relevant financial relationships ; Employee:BridgeBio:Active (exists now) ; Individual Stocks/Stock Options:BridgeBio:Active (exists now) ; Executive Role:BridgeBio:Active (exists now) | Jonathan Fox: No Answer | Jing Du: No Answer | Richard Cheng: DO NOT have relevant financial relationships | Margot Davis: DO have relevant financial relationships ; Speaker:Pfizer:Active (exists now) ; Consultant:Alnylam:Past (completed) ; Advisor:Ionis:Past (completed) ; Consultant:Novo Nordisk:Past (completed) ; Researcher:AstraZeneca:Active (exists now) | Amrut Ambardekar: DO NOT have relevant financial relationships | Jose Nativi-Nicolau: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) | Keyur Shah: DO have relevant financial relationships ; Consultant:BridgeBio:Active (exists now) ; Consultant:Pfizer :Past (completed) ; Research Funding (PI or named investigator):BridgeBio:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca :Active (exists now) | Mazen Hanna: DO have relevant financial relationships ; Advisor:Pfizer:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Alexion:Active (exists now) ; Advisor:BridgeBio:Active (exists now) ; Advisor:Alnylam:Active (exists now) | Simon Gibbs: No Answer | Jean-Francois Tamby: DO have relevant financial relationships ; Employee:BridgeBio Pharma:Active (exists now) | Suresh Siddhanti: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Cardiac Amyloidosis 2024: Advances in Prognostication and Management

Sunday, 11/17/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
Abrupt cardiac rupture of the patient with ATTR amyloidosis

Tagata Kento, Yutaro Nomoto, Tao Koji, Kataoka Tetsuro, Ohishi Mitsuru

A Case of Recurrent Acute Coronary Syndrome and Cardiogenic Shock due to Apolipoprotein A-IV Amyloidosis

Muthukkumar Rashmi, Holmes Taylor, Friede Kevin

More abstracts from these authors:
Acoramidis Reduces the Risk of All-Cause Mortality and Cardiovascular-Related Hospitalization Compared With Placebo in Participants With Transthyretin Amyloid Cardiomyopathy and Early-Stage Heart Failure Regardless of Atrial Fibrillation History: Insights From ATTRibute-CM

Witteles Ronald, Mitter Sumeet, Gillmore Julian, Hanna Mazen, Berk John, Mitchell Joshua, Shah Keyur, Kobayashi Masatake, Xiong Kuangnan, Castano Adam, Tamby Jean-francois, Fox Jonathan

Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results From the ATTRibute-CM Study

Davis Margot, Soman Prem, Kittleson Michelle, Berk John, Cao Xiaofan, Tamby Jean-francois, Castano Adam, Fox Jonathan, Shah Keyur, Grogan Martha, Griffin Jan, Sarswat Nitasha, Grodin Justin, Alexander Kevin, Judge Daniel, Gillmore Julian, Cappelli Francesco, Wright Richard

You have to be authorized to contact abstract author. Please, Login
Not Available